Compare VERX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | TSHA |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2020 | 2020 |
| Metric | VERX | TSHA |
|---|---|---|
| Price | $12.18 | $5.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $24.25 | $11.63 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $748,444,000.00 | $9,773,000.00 |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $11.61 | $1,152.42 |
| P/E Ratio | $302.25 | ★ N/A |
| Revenue Growth | 12.25 | ★ 17.28 |
| 52 Week Low | $10.59 | $2.25 |
| 52 Week High | $37.77 | $7.30 |
| Indicator | VERX | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 47.71 |
| Support Level | $12.16 | $5.27 |
| Resistance Level | $12.54 | $6.01 |
| Average True Range (ATR) | 0.67 | 0.35 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 10.87 | 49.33 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.